Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2025 08:57 ET | Source: Trethera Corporation

Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases,...
March 31, 2025 09:30 ET | Source: Trethera Corporation

Trethera Treats a Late Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE 515

LOS ANGELES, March 31, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through...
February 25, 2025 09:25 ET | Source: Trethera Corporation

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice

LOS ANGELES, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through...
January 15, 2025 09:52 ET | Source: Trethera Corporation

Trethera Announces Inflammatory Bowel Disease Poster Presentation at the Annual Crohn’s & Colitis Foundation Congress

LOS ANGELES, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
October 15, 2024 11:48 ET | Source: Trethera Corporation

Trethera Announces Presentation at the Rare Neuroimmune Disorders Symposium Annual Meeting

LOS ANGELES, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for...
July 16, 2024 08:37 ET | Source: Trethera Corporation

Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
September 25, 2023 11:22 ET | Source: Trethera Corporation

National Institute of Health to Fund Preclinical Development of Trethera Lead Drug, TRE-515, for Treatment of Crohn’s Disease

LOS ANGELES, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
September 05, 2023 10:55 ET | Source: Trethera Corporation

Globally Recognized Expert in Rare Neurologic Diseases, Dr. Michael Levy, Joins Trethera Scientific Advisory Board

LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
August 14, 2023 11:23 ET | Source: Trethera Corporation

Trethera Receives NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
June 27, 2023 11:14 ET | Source: Trethera Corporation

Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus

LOS ANGELES, June 27, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...

Next Page keyboard_arrow_right